Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML)
Giovanni Marconi(University of Bologna), Giovanni Martinelli(University of Bologna), Valentina Robustelli(University of Bologna), Simona Soverini(University of Bologna), Anna Ferrari(University of Bologna), Andrea Ghelli Luserna di Rorà(Fondazione Pisa), Chiara Sartor(University of Bologna), Maria Chiara Fontana(Istituto Oncologico Romagnolo), Maria Chiara Abbenante(University of Bologna), Emanuela Ottaviani(University of Bologna), Francesca Volpato(University of Bologna), Silvia Lo Monaco(University of Bologna), Eugenia Franchini(University of Bologna), Sarah Parisi(University of Bologna), Cristina Papayannidis(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Marco Manfrini(University of Padua), Giorgia Simonetti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Margherita Perricone(University of Bologna), Nicoletta Testoni(Thrombolysis in Myocardial Infarction Study Group), Viviana Guadagnuolo(University of Bologna), Elena Tenti(University of Bologna), Antonella Padella(University of Bologna), Stefania Paolini(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Carmen Baldazzi(University of Bologna), Maria Teresa Bochicchio(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori)
Cited by 1
Related Papers
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
|The Lancet Oncology|2019|486